BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Emphysema Market – Forecast to 2030,’ thoroughly examines the Emphysema industry to provide essential data & information for the targeted readers.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022.

United Spinal Association announced the appointment of Vice President of Tech Access, Adina Bradshaw, Director of Chapter Relations, Erin Gildner, and Director of Employment and DEI Programs, Lesly St. Louis to its staff.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference.

CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of preclinical data in EMBO Molecular Medicine that describes the potential utility for CRAC channel inhibitors in inflammatory bowel disease (IBD).

CereVasc, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt® System in patients who develop communicating hydrocephalus post aneurysmal subarachnoid hemorrhage (paSAH).

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.

CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended June 30, 2022.

Gossamer Bio today announced its financial results for the second quarter ended June 30, 2022 and provided a business update.